The study involves testing epcoritamab, administered subcutaneously, in combination with oral and intravenous anti-neoplastic agents. These include drugs like lenalidomide, ibrutinib, and polatuzumab ...

AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD) – UC ...

At a lymphoma conference, experts sparred about treatment options, while an outside expert highlighted the value of each approach.

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...

Rhythm Pharmaceuticals' experimental drug helped patients with a rare form of obesity caused by brain damage cut weight in a small study, the drugmaker said on Monday, sending its shares 24% higher in ...

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral treatment for a type of hereditary swelling disorder, sending its shares ...

FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

Novartis has chalked up another clinical trial win for its targeted factor B inhibitor iptacopan as it strives to position the drug as a patient-friendly, oral alternative to big-selling ...

Interleukin-2 (IL-2) inhibitors are immunosuppressive agents that block the activity of IL-2, a cytokine involved in the activation and proliferation ...

Promising Psoriasis Pipeline Therapies such as Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ ...

William Blair analysts project AbbVie to earn $16.15 per share by FY2028, a notable jump from its current $12.31 estimate.